

Ingrezza[™] (valbenazine) – New drug approval

- On April 11, 2017, the <u>FDA announced</u> the approval of <u>Neurocrine Biosciences</u> <u>Ingrezza</u> (<u>valbenazine</u>), for the treatment of adults with tardive dyskinesia (TD).
 - Ingrezza is the first FDA approved drug to treat TD.
- TD is a neurological disorder characterized by repetitive involuntary movements, usually of the jaw, lips, and tongue. Some affected individuals may also experience involuntary movement of the extremities or difficulty breathing.
 - TD is estimated to affect at least 500,000 Americans.
 - TD is sometimes seen in patients who have been treated with antipsychotic medications for long periods of time.
 - The symptoms of TD can be severe and are often persistent and irreversible.
- Ingrezza is a selective inhibitor of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.
- The safety and efficacy of Ingrezza were based on a placebo-controlled trial in 234 patients with moderate to severe TD. The primary endpoint was change from baseline in the Abnormal Involuntary Movement Scale (AIMS), a 12-item assessment of TD severity.
 - At the end of week 6, greater improvement in mean AIMS score occurred with Ingrezza vs.
 placebo. However, statistical significance was achieved only with the 80 mg dose.
- Warnings and precautions of Ingrezza include somnolence and QT prolongation.
- The most common adverse reaction (≥ 5% and twice the rate of placebo) with Ingrezza use was somnolence.
- The initial dose of Ingrezza is 40 mg orally once daily.
 - After one week, the recommended dose is 80 mg (2 capsules) once daily.
 - Continuation of 40 mg once daily may be considered in some patients.
- To assist TD patients with access to Ingrezza, Neurocrine Biosciences has created the INBRACE[™]
 patient support program, which is designed to provide personalized product assistance and services.
- Ingrezza will be in the distribution channel next week and will be available through a select pharmacy network. Ingrezza will be available as 40 mg capsules.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.